Skip to content
Therapeutics

Obesity & Cardiometabolic Diseases

Developing Breakthrough Antibody Therapeutics for Obesity and Cardiometabolic Diseases

We are developing breakthrough therapeutics for treating obesity and related cardiometabolic diseases to help people achieve high quality, durable weight loss and better overall metabolic health. While current glucagon-like peptide-1 receptor agonists (GLP-1s) have led to significant weight loss and improved health for many clinically obese patients, a new generation of therapeutics is needed to overcome their shortcomings, such as loss of muscle mass while on treatment, inconvenient dosing, and side effects that lead some patients to discontinue therapy. 

Our pipeline is initially focused on highly validated targets within the transforming growth factor beta (TGF-β) superfamily believed to inhibit muscle growth and balance calorie intake with calorie expenditure. By “inhibiting the inhibitors,” our therapeutic candidates have the potential to help patients retain and build muscle mass during and after weight loss with GLP-1s, while enhancing fat specific weight-loss for better health. 

iBio Announces Non-Human Primate Data for IBIO-600

Why Myostatin?

Myostatin, a member of the TGF-β superfamily, is a protein expressed by muscle cells that suppresses muscle growth. We are developing, for the first time, anti-myostatin therapeutics specifically tailored to treating obesity. In an exploratory study of non-human primates, IBIO-600, the company’s lead anti-myostatin therapeutic, demonstrated an extended half-life, indicating the potential for infrequent dosing intervals of 3-6 months, along with an increase in lean mass and reduction of fat mass.

IBIO-600 Potential Benefits and Differentiation*

  • Long-acting, first-in-class antibody targeting myostatin
  • Well-tolerated for long-term use
  • Infrequent dosing of 3-6 months
  • Increased lean mass and reduced fat mass
  • Subcutaneous self-administration

Myostatin x Activin A Bispecific Potential Benefits and Differentiation*

  • Long-acting, first-in-class bispecific antibody
  • Simultaneously inhibits myostatin and Activin A, another muscle-growth inhibitor
  • Potent obesity treatment capable of generating pronounced muscle growth
  • Treatment for pulmonary hypertension in heart failure with preserved ejection fraction, (PH-HfpEF) the most common type of heart failure
  • Bispecific enables highly selective inhibition of multiple inhibitors, unlike ligand trap approaches, which may block additional signaling molecules

Activin E

Along with Myostatin, we’re targeting Activin E, another member of the TGF-β superfamily. Rare loss of function mutations in the gene encoding Activin E, identified in human population studies, have been associated with reduced abdominal fat and reduced risk of cardiometabolic disease. By blocking Activin E, we aim to promote fat-specific weight loss and reduce the risk of cardiometabolic diseases.

Activin E Antagonist Potential Benefits and Differentiation*

  • First-in-class Activin E blocking antibody; a novel mechanism for pharmacological intervention
  • Fat-selective weight loss with potential to complement or offer an alternative to GLP-1s
  • Extended half-life for infrequent dosing every 3-6 months
  • Compatibility with anti-myostatin for bispecific development

Driving our cardiometabolic and obesity pipeline is iBio’s artificial intelligence-enabled discovery platform, an integrated technology stack for advancing antibodies against difficult targets. We’re using this scalable platform for chronic diseases such as obesity, with an eye toward other diseases where we can enhance quality of life, health span, and longevity. 

*iBio Announces IBIO-600 Non-Human Primate Data Showing Extended Half-Life and Muscle Growth, and Interim In Vivo Results for First-in-Class Activin E Antibody, Advancing Cardiometabolic and Obesity Pipeline

 

Top